Role of bone markers in monitoring the therapeutic effect of bisphosphonates in postmenopausal osteoporosis

Objective: Aim of the study was to detect values of bone markers as a way to reflect response to therapy in osteoporosis . Materials and methods: The study involved data of 73 female patients suffering from postmenopausal osteoporosis that were treated with bisphosphonates in the period of twelve months. Values of osteocalcin, P1NP and β-Cross Laps were measured before starting therapy, six months and twelve months after the start of therapy. Bone mass density (BMD) was measured with densitometry before therapy and twelve months after the start of therapy. Values of bone markers were determined by in vitro quantitative determination in human serum and plasma. Data base was configured in Microsoft Office Excel 2010. Statistical analysis was done by IBM SPSS Statistics v. 21.0 for Windows programme. Data was represented in table and graph form with help of classic methods of descriptive statistics. Results: Results in this study have showed significant reduction in serum values of bone formation markers (osteocalcin, P1NP) and also bone resorption markers (β-cross laps) after inducing bisphosphonate therapy in patients with postmenopausal osteoporosis during a period of 12 months.Results have also showed significant increase in bone mass density respectively increase in vertebral T-score values and also increase in femoral T-score values. Conclusion: dinamics of bone markers significantly reflects therapeutic effect of bisphosphonate therapy in postmenopausal osteoporosis. Keywords: osteoporosis, therapy, bisphosphonates, P1NP, osteocalcin, β-Cross Laps